Keros Therapeutics (KROS) EBT Margin (2019 - 2025)
Keros Therapeutics (KROS) reported EBT Margin of 4328.42% for Q4 2025, down 1332960.0% on a YoY basis from N/an in Q4 2024, and down 6992.37% quarter-over-quarter from 61.03% in Q3 2025.
Keros Therapeutics (KROS) EBT Margin (2019 - 2025) Analysis & Trends
Keros Therapeutics has reported EBT Margin for 6 years, with the latest figure at 4328.42% in Q4 2025.
- For the quarter ending Q4 2025, EBT Margin fell 1332960.0% year-over-year to 4328.42%; the trailing twelve-month figure through Dec 2025 stood at 37.62% (down 15583988.0% YoY), and the FY2025 full-year result was 37.65%, changed N/A from the prior year.
- EBT Margin for Q4 2025 stood at 4328.42%, down from 61.03% in the prior quarter.
- The five-year high for EBT Margin was 9001.18% in Q4 2024, with the low at 541000.0% in Q3 2023.
- Historically, EBT Margin has averaged 54401.17% across 5 years, with a median of 181.19% in 2025.
- Annual changes were most pronounced in 2024 — EBT Margin soared 52735155 bps — and 2025, when it sank 1332960 bps.
- Keros Therapeutics' EBT Margin stood at 27.6% in 2021, then plunged by 387 bps to 134.37% in 2022, then tumbled by 24077 bps to 32486.01% in 2023, then soared by 128 bps to 9001.18% in 2024, then plunged by 148 bps to 4328.42% in 2025.
- The last three EBT Margin figures came in at 4328.42% (Q4 2025), 61.03% (Q3 2025), and 181.19% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 6.40% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 41.95% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Keros Therapeutics | 399.01 Mn | 111.61 Mn | - | -4,328.42% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -4,328.42% |
| Sep 30, 2025 | -61.03% |
| Jun 30, 2025 | -181.19% |
| Mar 31, 2025 | 75.03% |
| Dec 31, 2024 | 9,001.18% |
| Sep 30, 2024 | -13,648.45% |
| Dec 31, 2023 | -32,486.01% |
| Sep 30, 2023 | -541,000.00% |
| Mar 31, 2022 | -134.37% |
| Dec 31, 2021 | -27.60% |
| Jun 30, 2021 | -15,622.00% |
| Dec 31, 2019 | -110.04% |
| Sep 30, 2019 | -141.96% |
| Jun 30, 2019 | -114.12% |
| Mar 31, 2019 | -127.32% |